Replimune Group Analyst Ratings
Replimune Group Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 152.65% | HC Wainwright & Co. | $51 → $50 | Maintains | Buy |
| 08/01/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/15/2023 | 152.65% | JP Morgan | $38 → $50 | Maintains | Overweight |
| 06/08/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/07/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 06/05/2023 | 157.71% | HC Wainwright & Co. | $50 → $51 | Maintains | Buy |
| 06/05/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/26/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/22/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 04/17/2023 | 122.33% | Piper Sandler | → $44 | Assumes | → Overweight |
| 02/10/2023 | 152.65% | HC Wainwright & Co. | $48 → $50 | Reiterates | → Buy |
| 01/05/2023 | 203.18% | EF Hutton | → $60 | Initiates Coverage On | → Buy |
| 12/12/2022 | 253.71% | BMO Capital | $40 → $70 | Maintains | Outperform |
| 12/07/2022 | 71.8% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 11/04/2022 | 142.55% | HC Wainwright & Co. | $60 → $48 | Maintains | Buy |
| 10/14/2022 | 102.12% | BMO Capital | $30 → $40 | Maintains | Outperform |
| 10/03/2022 | 51.59% | SVB Leerink | $37 → $30 | Maintains | Outperform |
| 08/16/2022 | 117.28% | Piper Sandler | $44 → $43 | Maintains | Overweight |
| 08/05/2022 | 86.96% | SVB Leerink | $48 → $37 | Maintains | Outperform |
| 05/24/2022 | 162.76% | Wedbush | $59 → $52 | Maintains | Outperform |
| 05/20/2022 | 142.55% | SVB Leerink | $49 → $48 | Maintains | Outperform |
| 04/04/2022 | 97.07% | JP Morgan | $47 → $39 | Maintains | Overweight |
| 03/18/2022 | 51.59% | BMO Capital | $51 → $30 | Maintains | Outperform |
| 11/19/2021 | 162.76% | Piper Sandler | → $52 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 147.6% | SVB Leerink | $55 → $49 | Maintains | Outperform |
| 08/09/2021 | 177.92% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 02/05/2021 | 203.18% | HC Wainwright & Co. | $58 → $60 | Maintains | Buy |
| 02/04/2021 | 182.97% | SVB Leerink | $57 → $56 | Maintains | Outperform |
| 11/17/2020 | 203.18% | BTIG | → $60 | Initiates Coverage On | → Buy |
| 11/10/2020 | 193.08% | HC Wainwright & Co. | $54 → $58 | Maintains | Buy |
| 11/06/2020 | 188.02% | BMO Capital | $51 → $57 | Maintains | Outperform |
| 10/15/2020 | 157.71% | BMO Capital | $40 → $51 | Maintains | Outperform |
| 10/15/2020 | 172.87% | HC Wainwright & Co. | $25 → $54 | Upgrades | Neutral → Buy |
| 10/15/2020 | 122.33% | SVB Leerink | $27 → $44 | Maintains | Outperform |
| 08/07/2020 | 36.43% | SVB Leerink | $25 → $27 | Maintains | Outperform |
| 07/01/2020 | 26.33% | HC Wainwright & Co. | → $25 | Downgrades | Buy → Neutral |
| 06/04/2020 | 26.33% | HC Wainwright & Co. | $24 → $25 | Maintains | Buy |
| 05/05/2020 | 6.11% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 01/21/2020 | 21.27% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 09/04/2019 | 1.06% | Roth Capital | → $20 | Initiates Coverage On | → Buy |
| 07/23/2019 | 41.49% | Chardan Capital | → $28 | Initiates Coverage On | → Buy |
| 07/12/2019 | 31.38% | JP Morgan | $27 → $26 | Upgrades | Neutral → Overweight |
| 07/08/2019 | 31.38% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/25/2019 | 21.27% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 01/23/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/14/2018 | 56.64% | BMO Capital | → $31 | Initiates Coverage On | → Outperform |
| 08/14/2018 | 31.38% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 152.65% | HC Wainwright公司 | $51→$50 | 维护 | 买 |
| 08/01/2023 | 157.71% | HC Wainwright公司 | →$51 | 重申 | 购买→购买 |
| 2023/06/15 | 152.65% | 摩根大通 | $38→$50 | 维护 | 超重 |
| 06/08/2023 | 157.71% | HC Wainwright公司 | →$51 | 重申 | 购买→购买 |
| 06/07/2023 | 162.76% | 韦德布什 | →$52 | 重申 | 跑赢→跑赢大盘 |
| 06/07/2023 | 203.18% | EF Hutton | →$60 | 重申 | 购买→购买 |
| 06/05/2023 | 157.71% | HC Wainwright公司 | $50→$51 | 维护 | 买 |
| 06/05/2023 | 203.18% | EF Hutton | →$60 | 重申 | 购买→购买 |
| 2023年05月26日 | 203.18% | EF Hutton | →$60 | 重申 | 购买→购买 |
| 2023年05月22日 | 162.76% | 韦德布什 | →$52 | 重申 | 跑赢→跑赢大盘 |
| 04/17/2023 | 122.33% | 派珀·桑德勒 | →$44 | 假设 | →超重 |
| 02/10/2023 | 152.65% | HC Wainwright公司 | $48→$50 | 重申 | →购买 |
| 01/05/2023 | 203.18% | EF Hutton | →$60 | 开始承保 | →购买 |
| 2022年12月12日 | 253.71% | 蒙特利尔银行资本 | $40→$70 | 维护 | 跑赢大盘 |
| 12/07/2022 | 71.8% | SVB Leerink | $30→$34 | 维护 | 跑赢大盘 |
| 11/04/2022 | 142.55% | HC Wainwright公司 | $60→$48 | 维护 | 买 |
| 10/14/2022 | 102.12% | 蒙特利尔银行资本 | $30→$40 | 维护 | 跑赢大盘 |
| 10/03/2022 | 51.59% | SVB Leerink | $37→$30 | 维护 | 跑赢大盘 |
| 08/16/2022 | 117.28% | 派珀·桑德勒 | $44→$43 | 维护 | 超重 |
| 08/05/2022 | 86.96% | SVB Leerink | $48→$37 | 维护 | 跑赢大盘 |
| 2022年05月24日 | 162.76% | 韦德布什 | $59→$52 | 维护 | 跑赢大盘 |
| 05/20/2022 | 142.55% | SVB Leerink | $49→$48 | 维护 | 跑赢大盘 |
| 04/04/2022 | 97.07% | 摩根大通 | $47→$39 | 维护 | 超重 |
| 03/18/2022 | 51.59% | 蒙特利尔银行资本 | $51→$30 | 维护 | 跑赢大盘 |
| 2021年11月19日 | 162.76% | 派珀·桑德勒 | →$52 | 开始承保 | →超重 |
| 2021/08/23 | 147.6% | SVB Leerink | $55→$49 | 维护 | 跑赢大盘 |
| 08/09/2021 | 177.92% | SVB Leerink | $56→$55 | 维护 | 跑赢大盘 |
| 02/05/2021 | 203.18% | HC Wainwright公司 | $58→$60 | 维护 | 买 |
| 02/04/2021 | 182.97% | SVB Leerink | $57→$56 | 维护 | 跑赢大盘 |
| 11/17/2020 | 203.18% | BTIG | →$60 | 开始承保 | →购买 |
| 11/10/2020 | 193.08% | HC Wainwright公司 | $54→$58 | 维护 | 买 |
| 11/06/2020 | 188.02% | 蒙特利尔银行资本 | $51→$57 | 维护 | 跑赢大盘 |
| 10/15/2020 | 157.71% | 蒙特利尔银行资本 | $40→$51 | 维护 | 跑赢大盘 |
| 10/15/2020 | 172.87% | HC Wainwright公司 | $25→$54 | 升级 | 中性→购买 |
| 10/15/2020 | 122.33% | SVB Leerink | $27→$44 | 维护 | 跑赢大盘 |
| 08/07/2020 | 36.43% | SVB Leerink | $25→$27 | 维护 | 跑赢大盘 |
| 07/01/2020 | 26.33% | HC Wainwright公司 | →$25 | 评级下调 | 购买→中性 |
| 06/04/2020 | 26.33% | HC Wainwright公司 | $24→$25 | 维护 | 买 |
| 05/05/2020 | 6.11% | 巴克莱 | →$21 | 开始承保 | →超重 |
| 2020/01/21 | 21.27% | HC Wainwright公司 | $26→$24 | 维护 | 买 |
| 2019年09月04日 | 1.06% | 罗斯资本 | →$20 | 开始承保 | →购买 |
| 2019年07月23日 | 41.49% | 查尔丹资本 | →$28 | 开始承保 | →购买 |
| 2019年07月12日 | 31.38% | 摩根大通 | $27→$26 | 升级 | 中性→超重 |
| 2019年07月08日 | 31.38% | HC Wainwright公司 | →$26 | 开始承保 | →购买 |
| 2019年04月25日 | 21.27% | 韦德布什 | →$24 | 开始承保 | →跑赢大盘 |
| 2019年01月23日 | - | 摩根大通 | 评级下调 | 超重→中性 | |
| 2018年08月14日 | 56.64% | 蒙特利尔银行资本 | →$31 | 开始承保 | →跑赢大盘 |
| 2018年08月14日 | 31.38% | 摩根大通 | →$26 | 开始承保 | →超重 |
What is the target price for Replimune Group (REPL)?
Replimune Group(REPL)的目标价是多少？
The latest price target for Replimune Group (NASDAQ: REPL) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $50.00 expecting REPL to rise to within 12 months (a possible 152.65% upside). 19 analyst firms have reported ratings in the last year.
复制集团(纳斯达克代码：REPL)的最新目标价是由HC Wainwright&Co.于2023年8月7日报道的。这家分析公司将目标价定为50美元，预计每股收益将在12个月内升至(可能上涨152.65)。去年有19家分析公司公布了评级。
What is the most recent analyst rating for Replimune Group (REPL)?
Replimune Group(REPL)的最新分析师评级是多少？
The latest analyst rating for Replimune Group (NASDAQ: REPL) was provided by HC Wainwright & Co., and Replimune Group maintained their buy rating.
对复制集团(纳斯达克代码：REPL)的最新分析师评级由HC Wainwright&Co.提供，复制集团维持其买入评级。
When is the next analyst rating going to be posted or updated for Replimune Group (REPL)?
Replimune Group(REPL)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Replimune Group的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Replimune Group的上一次评级是在2023年8月7日提交的，因此您应该预计下一次评级将在2024年8月7日左右提供。
Is the Analyst Rating Replimune Group (REPL) correct?
分析师评级Replimune Group(REPL)正确吗？
While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a maintained with a price target of $51.00 to $50.00. The current price Replimune Group (REPL) is trading at is $19.79, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Replimune Group(REPL)评级保持不变，目标价在51.00美元至50.00美元之间。Replimune Group(REPL)目前的交易价格为19.79美元，超出了分析师的预测区间。